Please see Indications and Important Safety Information on back cover, and accompanying Full Prescribing Information for Prevnar 13®.

See inside for tear pad of frequently asked questions for your patients.
Q. WHAT IS PNEUMOCOCCAL DISEASE?
A. Pneumococcal (NEU-mo-KOK-al) disease (PD) is caused by bacteria called *Streptococcus pneumoniae*. It can make you very sick. It’s spread from person to person by close contact.

Q. HOW CAN PD AFFECT ME?
A. Some people think PD is an illness that only old or sick people get, a disease only seen in hospitals or nursing homes. But each year in the US there are many types of PD reported: 7000 cases of blood infections, 442,000 cases of pneumonia, and 1700 cases of meningitis. Meningitis is an infection of the covering of the brain. It’s rare, but can be fatal.

Q. WHAT IS PREVNAR 13®?
A. Prevnar 13® is a vaccine that may help prevent some cases of pneumonia and other types of PD. There are more than 90 types of pneumococcal bacteria. Prevnar 13® only works against the 13 types of bacteria targeted by the vaccine. Prevnar 13® is given by injection.

Q. DOES PREVNAR 13® CONTAIN LIVE BACTERIA?
A. Prevnar 13® does not contain “live bacteria.” In simple terms, Prevnar 13® contains “killed bacteria” that create a kind of immune response to help protect the body against 13 types of pneumococcal bacteria.

Q. WHICH ADULTS SHOULD BE GIVEN PREVNAR 13®?
A. Prevnar 13® is indicated for adults 50 years of age and older. It’s given in 1 dose. Adults who have already received a pneumococcal polysaccharide vaccine (PPSV) can be vaccinated with Prevnar 13®. The effectiveness of Prevnar 13® when it’s given less than 5 years after a PPSV isn’t known. Ask your health care provider for details.

Q. WHY ARE PEOPLE 50+ AT INCREASED RISK FOR PNEUMOCOCCAL DISEASE?
A. As you get older, your immune system isn’t able to respond as well to infection as it did when you were younger. As you age, the number of available cells that protect you from infection is depleted—and you produce fewer of the chemicals and molecules necessary to rapidly defend yourself against a threat such as pneumococcal disease. By the time you reach age 50, your immune system may have declined enough to put you at increased risk for pneumococcal infection.

Q. CAN PEOPLE WITH MEDICAL CONDITIONS BE GIVEN PREVNAR 13®?
A. Yes. People can be given Prevnar 13® even if they have chronic heart disease, chronic obstructive pulmonary disease (COPD), diabetes, or chronic liver disease. Also, if they are alcohol dependent or smoke. Tell your health care provider about any medical conditions you may have. Prevnar 13® should not be given to anyone with a history of severe allergic reaction to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine.

Q. WHO SHOULD NOT BE GIVEN PREVNAR 13®?
A. Talk with your health care provider about whether Prevnar 13® is right for you. Prevnar 13® should not be given to anyone with a history of severe allergic reaction to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine.

Q. ARE THERE ANY RISKS ASSOCIATED WITH PREVNAR 13®?
A. Any medicine could possibly cause a serious problem. This includes vaccines. An example is a severe allergic reaction. In studies, Prevnar 13® was given to more than 5000 adults. These adults were 50 to 95 years old. Most reactions were mild. In adults, the common side effects were pain, redness, or swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, chills, or rash. Life-threatening allergic reactions from vaccines are very rare. If they do occur, it would be within a few minutes to a few hours after the injection.
Q. WHAT IF THERE IS A SEVERE REACTION?
A. WHAT SHOULD I LOOK FOR?

Any unusual condition, such as a high fever or behavior changes. Signs of a severe allergic reaction can include difficulty breathing, hoarseness or wheezing, hives, paleness, weakness, a fast heart beat, or dizziness.

WHAT SHOULD I DO?

• Call a doctor, or get the person to a doctor right away
• Tell the doctor what happened, the date and time it happened, and when the vaccination was given
• Ask your health care provider to report the reaction by filing a Vaccine Adverse Event Reporting System (VAERS) form. Or you can file this report through the VAERS Web site at www.vaers.hhs.gov, or by calling 1-800-822-7967

VAERS does not provide medical advice.

Q. HOW CAN I LEARN MORE?
A. Talk with your health care provider. Ask for the Prescribing Information for Prevnar 13® and suggestions for other sources of information. You can also:

• Go to http://www.adult.prevnar13.com
• Call your local or state health department
• Contact the Centers for Disease Control and Prevention (CDC) at 1-800-232-4636 (1-800-CDC-INF0)
• Go to http://www.cdc.gov/vaccines

INDICATIONS FOR PREVNAR 13®

• Prevnar 13® is a vaccine indicated for adults 50 years of age and older for the prevention of pneumococcal pneumonia and invasive disease caused by 13 Streptococcus pneumoniae strains (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). This indication is based upon immune responses to the vaccine
• In children 6 weeks through 5 years of age, Prevnar 13® is indicated for the prevention of invasive disease caused by these same strains, and for the prevention of ear infection caused by 7 of the 13 strains
• Prevnar 13® is not 100% effective and will only help protect against the 13 strains included in the vaccine
• Effectiveness when given less than 5 years after a pneumococcal polysaccharide vaccine is not known

IMPORTANT SAFETY INFORMATION

• Prevnar 13® should not be given to anyone with a history of severe allergic reaction to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine
• Children and adults with weakened immune systems (eg, HIV infection, leukemia) may have a reduced immune response
• In adults, the common side effects were pain, redness, or swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, chills, or rash
• In adults, immune responses to Prevnar 13® were reduced when given with injected seasonal flu vaccine
• A temporary pause of breathing following vaccination has been observed in some infants born prematurely
• The most commonly reported serious adverse events in children were bronchiolitis (an infection of the lungs) (0.9%), gastroenteritis (inflammation of the stomach and small intestine) (0.9%), and pneumonia (0.9%)
• In infants and toddlers, the most common side effects were tenderness, redness, or swelling at the injection site, irritability, decreased appetite, decreased or increased sleep, and fever
• Ask your health care provider about the risks and benefits of Prevnar 13®. Only a health care provider can decide if Prevnar 13® is right for you

Please see full Prescribing Information for Prevnar 13®.

PREVNAR 13 is a registered trademark of Wyeth LLC.
Administration of Prevnar 13® in adults

Preparation for administration
• Shake vigorously prior to use to obtain a homogeneous, white suspension in the vaccine container, since Prevnar 13® is a suspension containing an adjuvant
• Do not use the vaccine if it cannot be resuspended
• Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration

Prevnar 13® should not be used if particulate matter or discoloration is found

Administration
• Prevnar 13® is for intramuscular injection only
• Preferred site for injection in adults is the deltoid muscle of the upper arm
• Prevnar 13® should not be injected in the gluteal area or areas where there may be a major nerve trunk and/or blood vessel

Prevnar 13® should not be used if particulate matter or discoloration is found

INDICATIONS
• Prevnar 13® is a vaccine indicated for active immunization for the prevention of disease caused by
  - Pneumococcal polysaccharide vaccine serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, and 23F
• In adults 50 years and older for pneumococcal pneumonia and invasive disease. Indication is based on immune responses achieved by 1/4 of the 13 serotypes only

Limitations of Use and Effectiveness
• Prevnar 13® will only help protect against S pneumoniae serotypes in the vaccine
• Effectiveness when administered <5 years after pneumococcal polysaccharide vaccine is not known

IMPORTANT SAFETY INFORMATION
• Severe allergic reaction (e.g., anaphylaxis) to any component of Prevnar 13® or any diphtheria–tetanus–containing vaccine is a contraindication
• Immune-compromised individuals or individuals with impaired immune responses owing to the use of immunosuppressive therapy may have reduced antibody responses
• In adults, antibody responses to Prevnar 13® were diminished when given with inactivated Influenza Viral Vaccine
• In adults, the commonly reported solicited adverse reactions were pain, redness, and swelling at the injection site. Limitation of arm movement, fatigue, headache, muscle or joint pain, decreased appetite, chills, or rash

Apnea following intramuscular vaccination has been observed in neonatal rats (dose unspecified). Vaccination of premature infants should be based on the infant’s medical status, and the potential benefits and risks

Please see accompanying full Prescribing Information for Prevnar 13®.

To learn more about Prevnar 13®, please visit www.prevnar13adulthcp.com

PREVNAR 13 is a registered trademark of Wyeth LLC.
Manufactured by Wyeth Pharmaceuticals Inc.
Marketed by Pfizer Inc.
PSA290062-01 © 2012 Pfizer Inc.
All rights reserved.
Printed in USA/ March 2012